<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05053100</url>
  </required_header>
  <id_info>
    <org_study_id>MC210804</org_study_id>
    <secondary_id>NCI-2021-09154</secondary_id>
    <secondary_id>MC210804</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT05053100</nct_id>
  </id_info>
  <brief_title>Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study</brief_title>
  <official_title>Hemorrhage and Thrombosis in Hematology Malignancies: Understanding the Risks of Thrombosis and Anticoagulation in Patients With Hematologic Malignancies (HAT Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the risks and experience of blood clots and bleeding in patients with&#xD;
      blood cancers. While it is standard of care to use medications to reduce the risk of blood&#xD;
      clots in hospitalized individuals, some patients with blood cancers have low platelet counts&#xD;
      that can increase the concern for bleeding complications associated with these medications.&#xD;
      At this time, the optimal management strategies for blood clots are not well known for&#xD;
      patients with blood cancers. This pilot study evaluates additional information that could&#xD;
      help doctors know which patients are at highest risk for blood clots.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the incidence of hemorrhage in the 3 months following deep vein thrombosis&#xD;
      diagnosis in hospitalized malignant hematology patients, based on anticoagulant use and&#xD;
      presence of thrombocytopenia.&#xD;
&#xD;
      II. Determine recurrent or progressive venous thromboembolism in the 3 months following deep&#xD;
      vein thrombosis diagnosis in hospitalized malignant hematology patients, based on&#xD;
      anticoagulant use and presence of thrombocytopenia.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Assess feasibility of database creation of patient and clinical characteristics regarding&#xD;
      thrombosis and hemorrhage in hospitalized malignant hematology patients.&#xD;
&#xD;
      II. Assess feasibility of patient enrollment and hemostatic laboratory collection pre, during&#xD;
      and post treatment.&#xD;
&#xD;
      III. Describe the impact of thrombocytopenia on resource utilization following thrombosis&#xD;
      diagnosis (blood product administration, imaging studies performed, number of days&#xD;
      hospitalized).&#xD;
&#xD;
      IV. Describe the impact of therapeutic anticoagulation vs prophylactic anticoagulation on&#xD;
      resource utilization following thrombosis diagnosis (blood product administration, imaging&#xD;
      studies performed, number of days hospitalized).&#xD;
&#xD;
      V. Define baseline hemostatic characteristics in hospitalized malignant hematology patients&#xD;
      prior to chemotherapy and the association with thrombosis or hemorrhage.&#xD;
&#xD;
      VI. Describe changes in laboratory hemostatic characteristics pre-treatment, during treatment&#xD;
      and post treatment.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients' electronic health record are reviewed for 12 months and/or undergo collection of&#xD;
      blood at pretreatment and on days 7, 28, 90, and 180.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">August 18, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 18, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombosis incidence</measure>
    <time_frame>Time between admission to the hospital and venous thrombotic event, assessed up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of venous thromboembolism recurrence</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Kaplan-Meier curve is created and compared by anticoagulation strategy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemorrhage incidence, without prior thrombosis</measure>
    <time_frame>Time between admission to the hospital and hemorrhage event, assessed up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhage incidence, with prior thrombosis &lt; 12 months</measure>
    <time_frame>Within 3 months following deep vein thrombosis diagnosis</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Leukemia</condition>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Myeloproliferative Neoplasm</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Plasma Cell Myeloma</condition>
  <condition>Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Observational (record review, blood collection)</arm_group_label>
    <description>Patients' electronic health record are reviewed for 12 months and/or undergo collection of blood at pretreatment and on days 7, 28, 90, and 180.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo collection of blood</description>
    <arm_group_label>Observational (record review, blood collection)</arm_group_label>
    <other_name>Biological Sample Collection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic Health Record Review</intervention_name>
    <description>Undergo electronic health record review</description>
    <arm_group_label>Observational (record review, blood collection)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to Mayo Clinic Arizona Hematology.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All unique patients, age &gt; 18 years old, admitted to the Mayo Clinic Arizona&#xD;
             Hematology A and B Service for initiation of 1.) new (or next line) chemotherapy, 2.)&#xD;
             autologous stem cell transplant, or 3.) allogeneic stem cell transplant for a&#xD;
             hematologic malignancy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Solid tumor malignancy patients&#xD;
&#xD;
          -  Age &lt; 18&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie J Padrnos</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
      <email>mayocliniccancerstudies@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Leslie J. Padrnos, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

